ADXS — Ayala Pharmaceuticals Balance Sheet
0.000.00%
- $1.28m
- $4.21m
- $0.01m
Annual balance sheet for Ayala Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 October 31st | 2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 32.4 | 25.2 | 41.6 | 25.2 | 5.21 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0 | — | — | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 36.1 | 27.9 | 43.3 | 25.8 | 7.53 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4.35 | 7.23 | 0.158 | 0.05 | 0.642 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 45.3 | 38.5 | 46.8 | 25.9 | 16.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.52 | 3.29 | 7.88 | 2.3 | 25 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 5.73 | 8.35 | 7.89 | 2.3 | 41 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 39.5 | 30.2 | 38.9 | 23.6 | -24.4 |
Total Liabilities & Shareholders' Equity | 45.3 | 38.5 | 46.8 | 25.9 | 16.6 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |